← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Xoma Corporation
Berkeley, CA
$84,860,488
Total funding
3
Grants
Funding over time
peak $19.9M · FY2008–14$20M$15M$10M$5M$0
'08
'09
'10
'11
'12
'13
'14
Funding mix
By agency
NIH$84,860,488 · 3
By mechanism
N01$84,860,488 · 3
Investigators at Xoma Corporation
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
Not enough data
All-Time
Most funded here, all years
Not enough data
Largest grants
Monoclonal Antibody-Based Therapeutics for Botulism$19,916,229
N01 · FY2008 · AI
Monoclonal Antibody-Based Therapeutics for Botulism$15,013,143
N01 · FY2012 · AI
Monoclonal Antibody-Based Therapeutics for Botulism$12,082,342
N01 · FY2011 · AI
Monoclonal Antibody-Based Therapeutics for Botulism$11,731,128
N01 · FY2010 · AI
BROAD SPECTRUM MONOCLONAL ANTIBODY-BASED THERAPEUTIC FOR BOTULISM$10,911,958
N01 · FY2014 · AI
BROAD SPECTRUM MONOCLONAL ANTIBODY-BASED THERAPEUTIC FOR BOTULISM$7,078,812
N01 · FY2011 · AI
BROAD SPECTRUM MONOCLONAL ANTIBODY-BASED THERAPEUTIC FOR BOTULISM$5,969,753
N01 · FY2013 · AI
Development of Monoclonal Antibody-Based Therapeutics for Botulism$2,157,123
N01 · FY2012 · AI